Use of psychedelics is on the rise in Canada. Doctors are starting to look at long-term risks, benefits

A recent study has found that individuals who use prohibited psychedelics such as psilocybin or LSD and end up in the emergency department for care have a higher risk of death within five years compared to the general population in Canada. Psychedelics, a subclass of hallucinogenic drugs, have been gaining popularity in recent years, with the use of substances like ketamine, psilocybin, ayahuasca, and MDMA or ecstasy on the rise in both Canada and the United States.

Dr. Daniel Myran, a family physician and researcher at the University of Ottawa, noted that the use of psychedelics has been increasing among Canadians, with as many as 5.9 per cent of individuals reported using substances like psilocybin in 2023. This trend is particularly prevalent among young adults aged 20–24, with a reported usage rate of 13.9 per cent. While some individuals use psychedelics for therapeutic purposes, such as microdosing psilocybin under supervised treatment, others engage in recreational use of these illegal substances.

In a study published in the Canadian Medical Association Journal, Dr. Myran and his team investigated the potential long-term effects of using hallucinogens, specifically examining the risk of death associated with their use. By analyzing health care data from over 11.4 million individuals in Ontario, the researchers found that those who sought acute care for hallucinogen use had a significantly higher risk of death within five years compared to the general population of the same age and sex.

While the study did not establish a direct cause-and-effect relationship between hallucinogen use and death, researchers observed associations with suicide, other drug poisonings, lung disease, and cancer among individuals who had sought medical care for hallucinogen-related issues. The study also highlighted the presence of chronic health conditions and substance use problems among individuals using hallucinogens, underscoring the importance of medical supervision and interventions for this high-risk group.

Dr. Jennifer Swainson, a psychiatrist at the University of Alberta, emphasized the need for proper medical supervision when using psychedelics, especially for individuals with underlying mental health issues or substance use risks. While psychedelic-assisted therapy shows promise for treating conditions like PTSD and treatment-resistant depression, misuse of these substances outside of clinical settings can pose significant risks.

Overall, the study underscores the importance of ongoing research and education on the potential benefits and risks of hallucinogen use. As the popularity of psychedelics continues to rise, it is crucial for individuals to be aware of the potential dangers associated with these substances and seek proper medical guidance when considering their use. If you or someone you know is struggling, it is important to seek help from qualified healthcare professionals to ensure safety and well-being.